文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

早期cT3c视网膜母细胞瘤的保眼治疗

Eye-Preserving Therapies for Early cT3c Retinoblastoma.
PubMed 文献 · Ophthalmology · 2026-07-24

该回顾性单中心队列研究纳入132例早期cT3c视网膜母细胞瘤患者,比较初次保眼治疗与初次眼球摘除。中位随访52.9个月,两组总生存无显著差异(P=0.775)。保眼治疗组眼球 salvage 率为49.4%,其中46.3%的保留眼恢复光感或更好视力。眼压≥32 mmHg和角膜水肿是保眼失败的高危因素。

要点

  • 早期cT3c视网膜母细胞瘤初次保眼治疗不损害总体生存。
  • 保眼治疗组眼球 salvage 率为49.4%,部分保留眼恢复有用视力。
  • 眼压≥32 mmHg和角膜水肿预示保眼失败风险显著增高。

核心结论

  • 初次保眼治疗可在不危及生存的前提下,为早期cT3c视网膜母细胞瘤患者获得较高的眼球 salvage 率并保留部分视功能。
  • 存在角膜水肿或眼压≥32 mmHg的眼球 salvage 结局明显更差,治疗需谨慎个体化。

研究设计与样本

  • 回顾性单中心队列研究,纳入2014年5月至2024年10月诊断为早期cT3c视网膜母细胞瘤的132例患者。
  • 患者分为初次眼球摘除组(50例)和初次保眼治疗组(82例),随访生存状态和眼部结局。

主要发现

  • 中位随访52.9个月,保眼组与摘除组各死亡1例,总生存无显著差异(log-rank检验,P=0.775)。
  • 保眼治疗与高危病理特征发生率较低相关(OR=0.21;P=0.003),脉络膜侵犯(OR=0.25;P=0.002)和视神经侵犯(OR=0.23;P=0.008)的严重程度均减轻。
  • 初次保眼治疗组眼球 salvage 率为49.4%(41/83),其中46.3%(19/41)的保留眼恢复光感或更好视力。
  • 眼压≥32 mmHg(HR=2.37;P=0.010)和角膜水肿(HR=2.86;P=0.007)是眼球 salvage 失败的高危因素。
  • 与单纯静脉化疗相比,单纯动脉内化疗(HR=0.13;P=0.001)及静脉化疗联合动脉内化疗(HR=0.15;P=0.001)与更好的眼球 salvage 结局显著相关。

关键数值与推荐

  • 早期cT3c定义为美国癌症联合委员会第八版分期中伴有新生血管性青光眼但无眼球突出的视网膜母细胞瘤。
  • 眼球 salvage 失败高危因素:初诊眼压≥32 mmHg(HR=2.37;P=0.010)和角膜水肿(HR=2.86;P=0.007)。
  • 冷冻治疗是总体眼球 salvage 的独立保护因素(HR=0.14;P<0.001)。

临床怎么用

  • 对早期cT3c视网膜母细胞瘤可考虑初次保眼治疗,但需密切监测生存和眼部结局。
  • 初诊眼压≥32 mmHg或存在角膜水肿者,保眼失败风险高,应个体化权衡治疗策略。
  • 动脉内化疗(单独或联合静脉化疗)及冷冻治疗可能与更好的保眼结局相关。

局限性

  • 回顾性单中心研究设计可能引入选择偏倚。
  • 样本量有限,部分亚组分析效能不足。
  • 随访时间中位52.9个月,长期结局仍需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and effectiveness of eye-preserving therapies in patients with retinoblastoma presenting with neovascular glaucoma without buphthalmos (defined as early cT3c by the American Joint Committee on Cancer Staging Manual, eighth edition), focusing on overall survival and eye preservation. DESIGN: Retrospective, single-center cohort study. PARTICIPANTS: A total of 132 patients diagnosed with early cT3c retinoblastoma from May 2014 through October 2024. METHODS: The patients were divided into primary enucleation (50 patients) and primary eye-preserving (82 patients) groups. They were followed up for survival status and ocular outcomes. MAIN OUTCOME MEASURES: Overall survival, high-risk pathologic features, globe salvage, and vision preservation. RESULTS: After a median follow-up of 52.9 months, 1 death occurred in each group, and overall survival did not differ significantly between the primary eye-preserving and primary enucleation groups (log-rank test, P = 0.775). Eye-preserving therapies were associated with a lower incidence of high-risk pathologic features (odds ratio [OR], 0.21; P = 0.003), with attenuated severity of both choroidal (OR, 0.25; P = 0.002) and optic nerve invasions (OR, 0.23; P = 0.008). The globe salvage rate was 49.4% (41 of 83) in the primary eye-preserving group. Among these preserved eyes, 46.3% (19 of 41) regained light perception or better after receiving eye-preserving therapies. Importantly, presenting intraocular pressure ≥32 mmHg (hazard ratio [HR], 2.37; P = 0.010) and corneal edema (HR, 2.86; P = 0.007) were high-risk factors for globe salvage failure. Compared with intravenous chemotherapy alone, application of intra-arterial chemotherapy (HR, 0.13; P = 0.001) alone and combined intravenous chemotherapy-intra-arterial chemotherapy regimens (HR, 0.15; P = 0.001) demonstrated a significant association with better globe salvage outcomes. Additionally, cryotherapy (HR, 0.14; P < 0.001) was identified as an independent protective factor for overall globe salvage. CONCLUSIONS: Primary eye-preserving therapies can secure high rates of globe salvage with partial visual function in patients with early cT3c retinoblastoma, without jeopardizing patient survival. However, eyes exhibiting corneal edema or intraocular pressure ≥32 mmHg demonstrate markedly inferior salvage outcomes; the treatment strategy for such patients must therefore be cautiously individualized. FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Xu Z, Yao Y, Yang J, et al. Eye-Preserving Therapies for Early cT3c Retinoblastoma. Ophthalmology. 2026. PMID: 42498083. doi:10.1016/j.ophtha.2026.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。